-
-
Single-molecule live-cell RNA imaging with CRISPR–Csm Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-18 Chenglong Xia, David Colognori, Xueyang Stephen Jiang, Ke Xu, Jennifer A. Doudna
-
Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-18 Zachary R. Baker, Yao Zhang, Haiyan Zhang, Hollyn C. Franklin, Priscila B. S. Serpa, Teresa Southard, Liwu Li, Bryan B. Hsu
-
Vertex’s opioid-free drug for acute pain wins FDA approval Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-17
Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation of addiction-free pain drugs acting at NaV1.8 sodium channels.
-
The reverse transcriptase domain of prime editors contributes to DNA repair in mammalian cells Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-17 Chunwei Zheng, Gangming Zhang, Lilia J. Dean, Erik J. Sontheimer, Wen Xue
-
Antibodies Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Recent patents relating to antibody compositions and methods of use.
-
Biotech news from around the world Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
The UK government says it will introduce in parliament by the end of March the legislation needed to implement new precision breeding rules. The new law will allow gene-edited plants to be commercialized in the UK. In the European Union, gene editing and other precision breeding techniques are effectively banned for cultivation, as they fall under the same regulations as genetically modified crops
-
Heat-resistant rice without yield compromise Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14 Alexandra Despang
In the face of global warming, producing stress- and heat-resistant plants has been a long-standing goal in plant breeding and genetics. Strategies like transcriptional regulation and gene overexpression for thermotolerance often reduce crop yields. Now, in Nature Genetics, Lu et al. report a wax biosynthesis module that can be genetically engineered to enhance rice yield under heat stress without
-
Gene and cell therapies for Parkinson’s make headway Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
An investigational gene therapy to treat Parkinson’s disease entered phase 2 studies in January. AskBio, a Bayer-owned company, will deploy an adeno-associated virus serotype 2 (AAV) delivered into the brain in randomized, double-blind studies in adults with moderate Parkinson’s. The AB-1005 therapy will deliver human glial cell line-derived neurotrophic factor (GDNF) genes into neurons to promote
-
Largest proteome study enlists 14 biopharmas Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Top biopharma companies have joined forces to conduct the biggest proteomics study yet, aimed at understanding how fluctuations in protein levels influence disease. The UK Biobank Pharma Proteomics Project will analyze 5,400 protein markers across 600,000 blood samples — half a million held in the UK Biobank from middle-aged participants recruited between 2006 and 2010, and 100,000 second samples taken
-
De novo-designed protein binders neutralize snake toxins Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14 Anahita Bishop
Three-finger toxins are the major component of the venom of elapid snakes and have limited immunogenicity in antivenom-producing animals, which results in a weak antibody response. Current treatments comprising polyclonal antibodies therefore often lack efficacy in preventing neurotoxicity and tissue necrosis. In a recent study published in Nature, Torres et al. use deep-learning methods to produce
-
Startup grows egg proteins in potato fields Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Ovalbumin, the main protein in egg whites, is sought after as an ingredient by food manufacturers as it helps to boost nutritional value and extend the shelf life of packaged products. The team engineered the potato by inserting the entire ovalbumin DNA sequence into the leaf, which thus contained instructions to produce a fully functional protein that is nutritionally and chemically identical to that
-
A chromatin-based model for deciphering gene interactions Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14 Rong Li
Foundation models have leveraged diverse gene expression profiles for tasks such as cell type annotation or prediction of perturbation response. However, no model yet exists to demonstrate how the chromatin landscape regulates transcription. Writing in Nature, Lu et al. introduce the general expression transformer (GET), a foundation model trained on chromatin accessibility data from diverse human
-
Colossal raises $200 million to bring back the dodo Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Real-life Jurassic Park startup Colossal BioSciences announced January 15 that it has raised $200 million to bring back three extinct animals: the woolly mammoth, the Tasmanian tiger and the dodo bird. Resurrecting an extinct ancient species would be a first that would require Colossal researchers to overcome some colossal challenges. The company says it has amassed the most continuous and complete
-
People Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Recent moves of note in and around the biotech and pharma industries.
-
AI biotechs launch bioprospecting expeditions with Indigenous groups, agree to share benefits Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14
Companies are striking unconventional benefit-sharing agreements with national governments to scour planet hotspots, gathering thousands of new DNA and protein sequences to develop into new, commercially useful molecules.
-
Undergraduate education as catalyst for public–private partnership in biotechnology Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14 Toine ten Broeke, Thijs Koorman, Sandra Crnko, Erik Voets, Pauline de Goeje, Michael Y. Schakelaar, Heggert G. Rebel, Emma W. Pijnappel, Jorine G. F. Sanders, Jan Meeldijk, Rian Terveer-Couperus, Esther L. Geven, Gönül Dilaver, Erik van Tilborg, Lucas M. P. Beekman, Lars Guelen, Niels Bovenschen
-
Redefining antibody patent protection using paratope mapping and CDR-scanning Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-14 Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson, Ulrich Storz, Benjamin J. Doranz
-
Gains in early-onset dementia with progranulin open new paths for drug discovery Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-11
The first clinical results in patients with a genetic form of frontotemporal dementia (FTD) show that enhancing progranulin in the brain may halt disease progression. If successful, this potentially disease-modifying approach may uncover new avenues for treating other neurodegenerative diseases.
-
Precise RNA targeting with CRISPR–Cas13d Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-11 Sydney K. Hart, Simon Müller, Hans-Hermann Wessels, Alejandro Méndez-Mancilla, Gediminas Drabavicius, Olivia Choi, Neville E. Sanjana
-
SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-05 Christopher R. Chang, Vivasvan S. Vykunta, Jae Hyun J. Lee, Ke Li, Clara Kochendoerfer, Joseph J. Muldoon, Charlotte H. Wang, Thomas Mazumder, Yang Sun, Daniel B. Goodman, William A. Nyberg, Chang Liu, Vincent Allain, Allison Rothrock, Chun J. Ye, Alexander Marson, Brian R. Shy, Justin Eyquem
-
Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-05 Manthan N. Patel, Sachchidanand Tiwari, Yufei Wang, Sarah O’Neill, Jichuan Wu, Serena Omo-Lamai, Carolann Espy, Liam S. Chase, Aparajeeta Majumder, Evan Hoffman, Anit Shah, András Sárközy, Jeremy Katzen, Norbert Pardi, Jacob S. Brenner
-
-
Sound healing and beyond Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-04
Ultrasound neurotechnologies are moving quickly into clinical trials in a wide variety of applications, and initiatives to open-source their manufacture will make them more accessible.
-
Implantation of engineered adipocytes suppresses tumor progression in cancer models Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-04 Hai P. Nguyen, Kelly An, Yusuke Ito, Bhushan N. Kharbikar, Rory Sheng, Breanna Paredes, Elizabeth Murray, Kimberly Pham, Michael Bruck, Xujia Zhou, Cassandra Biellak, Aki Ushiki, Mai Nobuhara, Sarah L. Fong, Daniel A. Bernards, Filipa Lynce, Deborah A. Dillon, Mark Jesus M. Magbanua, Laura A. Huppert, Heinz Hammerlindl, Jace Anton Klein, Luis Valdiviez, Oliver Fiehn, Laura Esserman, Tejal A. Desai
-
Quantifying metabolites using structure-switching aptamers coupled to DNA sequencing Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-04 June H. Tan, Andrew G. Fraser
-
Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-03 Feifei Zhang, Ryan D. Chow, Emily He, Chuanpeng Dong, Shan Xin, Daniyal Mirza, Yanzhi Feng, Xiaolong Tian, Nipun Verma, Medha Majety, Yueqi Zhang, Guangchuan Wang, Sidi Chen
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02535-2, published online 16 January 2025.
-
Author Correction: Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells Nat. Biotechnol. (IF 33.1) Pub Date : 2025-02-03 Pritha Agarwalla, Edikan A. Ogunnaike, Sarah Ahn, Kristen A. Froehlich, Anton Jansson, Frances S. Ligler, Gianpietro Dotti, Yevgeny Brudno
-
AAV vectors tested in perfused human livers Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-29 Roland W. Herzog, Ype P. de Jong
-
A neural network for long-term super-resolution imaging of live cells with reliable confidence quantification Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-29 Chang Qiao, Shuran Liu, Yuwang Wang, Wencong Xu, Xiaohan Geng, Tao Jiang, Jingyu Zhang, Quan Meng, Hui Qiao, Dong Li, Qionghai Dai
-
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-29 Jae-Jun Kim, Simone N. T. Kurial, Pervinder K. Choksi, Miguel Nunez, Tyler Lunow-Luke, Jan Bartel, Julia Driscoll, Chris L. Her, Simaron Dhillon, William Yue, Abhishek Murti, Tin Mao, Julian N. Ramos, Amita Tiyaboonchai, Markus Grompe, Aras N. Mattis, Shareef M. Syed, Bruce M. Wang, Jacquelyn J. Maher, Garrett R. Roll, Holger Willenbring
-
Unlocking drug modes of action with multi-dimensional high-throughput metabolic profiling Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-28
-
A human metabolic map of pharmacological perturbations reveals drug modes of action Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-28 Laurentz Schuhknecht, Karin Ortmayr, Jürgen Jänes, Martina Bläsi, Eleni Panoussis, Sebastian Bors, Terézia Dorčáková, Tobias Fuhrer, Pedro Beltrao, Mattia Zampieri
-
Uniform volumetric single-cell processing for organ-scale molecular phenotyping Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-24 Dae Hee Yun, Young-Gyun Park, Jae Hun Cho, Lee Kamentsky, Nicholas B. Evans, Nicholas DiNapoli, Katherine Xie, Seo Woo Choi, Alexandre Albanese, Yuxuan Tian, Chang Ho Sohn, Qiangge Zhang, Minyoung E. Kim, Justin Swaney, Webster Guan, Juhyuk Park, Gabi Drummond, Heejin Choi, Luzdary Ruelas, Guoping Feng, Kwanghun Chung
-
A platform for the biomedical application of large language models Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-22 Sebastian Lobentanzer, Shaohong Feng, Noah Bruderer, Andreas Maier, Cankun Wang, Jan Baumbach, Jorge Abreu-Vicente, Nils Krehl, Qin Ma, Thomas Lemberger, Julio Saez-Rodriguez
-
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-22 Mohammad Ghazi Vakili, Christoph Gorgulla, Jamie Snider, AkshatKumar Nigam, Dmitry Bezrukov, Daniel Varoli, Alex Aliper, Daniil Polykovsky, Krishna M. Padmanabha Das, Huel Cox III, Anna Lyakisheva, Ardalan Hosseini Mansob, Zhong Yao, Lela Bitar, Danielle Tahoulas, Dora Čerina, Eugene Radchenko, Xiao Ding, Jinxin Liu, Fanye Meng, Feng Ren, Yudong Cao, Igor Stagljar, Alán Aspuru-Guzik, Alex Zhavoronkov
-
Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-20
-
Pricey sickle cell gene therapies primed for change Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
Bluebird Bio and Vertex Pharmaceuticals are the first to participate in a scheme to enable people with sickle cell disease to access treatments they would otherwise not be able to afford. Gene and cell therapies are lifechanging treatments but remain some of the world’s most expensive drugs. The developers have agreed to join the Cell and Gene Therapy Access Model, due to launch in early 2025. The
-
Mushroom makes tasty eco-asphalt Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
Traditionally bitumen, which is made by crude oil distillation, has been used to bind gravel and sand to create our highways and roads. However, Visibuilt is ready to replace the fossil fuel with mycelium, the root-like structure of fungi. Demand for bitumen is high: 90% of our roads are made with asphalt. According to a report published by the International Bitumen Emulsion Federation, the estimated
-
Liver-avoiding capsids draw $1.1 billion Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
Novartis is shoring up its portfolio on gene therapies for inherited neuromuscular diseases by acquiring Kate Therapeutics in a deal worth up to $1.1 billion in up-front and milestone payments. The biotech company is developing preclinical therapeutic candidates for Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy and myotonic dystrophy type 1. It has also developed a platform for generating
-
Biotech news from around the world Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
1.UNITED KINGDOM The University of Oxford enters a strategic partnership with the Ellison Institute of Technology (EIT) to develop solutions in health and medicine, food security and sustainable agriculture, climate change and clean energy, and AI innovation. EIT is building a campus at the Oxford Science Park, with research labs, educational spaces, supercomputing facilities and an oncology and preventative
-
Synthetic GPCRs for controlling cellular responses Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Iris Marchal
Synthetic receptors, such as chimeric antigen receptors, are a powerful tool to modulate cell behavior for therapeutic purposes. However, engineering synthetic G-protein-coupled receptors (GPCRs) — the largest family of cell surface receptors — has been notoriously difficult. Writing in Nature, Kalogriopoulos et al. now create synthetic GPCRs with a modular antigen gate. These receptors can be programmed
-
Therapeutic T cells with synthetic gene circuits act locally Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Iris Marchal
Equipping immune cells with synthetic receptors is an important strategy to expand the repertoire of immunotherapies. Two papers in Science describe the development of T cells with synthetic Notch (synNotch) receptors to induce gene circuits that trigger the production of therapeutic payloads to treat central nervous system (CNS) and inflammatory diseases. Simic et al. engineered a synNotch receptor
-
Ionis wins FDA nod for triglyceride-lowering rare disease drug Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug Tryngolza (olezarsen), as an adjunct to a low-fat diet, to treat familial chylomicronemia syndrome (FCS). The RNA-targeted medicine is the first approved for this group of rare genetic disorders, in which the body cannot break down chylomicrons (lipoprotein particles, made up of about 90% triglycerides). In the United States
-
An organoid model with all three pancreatic lineages resembles fetal pancreas Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Iris Marchal
In many applications of organoid technology, improving model complexity to more closely resemble the native tissue is a major goal. Such is the case for pancreatic organoids, which so far have not recapitulated the full complement of cell types present in their human counterpart. In a paper now published in Cell, Andersson-Rolf et al. introduce an organoid model that more closely mimics the human pancreas
-
Cancer vaccines Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
Recent patents relating to compositions and methods for producing and using cancer vaccines.
-
People Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17
Recent moves of note in and around the biotech and pharma industries.
-
How will AI affect patent disclosures? Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Lisa Larrimore Ouellette, Victoria Fang, Nicholas T. Ouellette
Artificial intelligence tools for drafting patents will exacerbate challenges with the disclosure of useful technical information in patent documents.
-
Five questions with Anastassia Vorobieva Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Michael Francisco
A biophysicist interested in understanding the molecular principles of membrane protein folding and applying them to protein design discusses her nonlinear academic path and the potential societal impact of her research.
-
As new cell and gene therapies emerge from academia, we must RISE to the opportunity Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-17 Nandhitha Uma Naresh, Dana Hammill, Mark Kessel, Roger J. Hajjar, Nathan L. Yozwiak
-
Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-16 Feifei Zhang, Ryan D. Chow, Emily He, Chuanpeng Dong, Shan Xin, Daniyal Mirza, Yanzhi Feng, Xiaolong Tian, Nipun Verma, Medha Majety, Yueqi Zhang, Guangchuan Wang, Sidi Chen
-
Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-14 Jie Luo, Muge Molbay, Ying Chen, Izabela Horvath, Karoline Kadletz, Benjamin Kick, Shan Zhao, Rami Al-Maskari, Inderjeet Singh, Mayar Ali, Harsharan Singh Bhatia, David-Paul Minde, Moritz Negwer, Luciano Hoeher, Gian Marco Calandra, Bernhard Groschup, Jinpeng Su, Ceren Kimna, Zhouyi Rong, Nikolas Galensowske, Mihail Ivilinov Todorov, Denise Jeridi, Tzu-Lun Ohn, Stefan Roth, Alba Simats, Vikramjeet
-
Publisher Correction: Engineered platelets as targeted protein degraders and application to breast cancer models Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-13 Yu Chen, Samira Pal, Wen Li, Fengyuan Liu, Sichen Yuan, Quanyin Hu
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02494-8, published online 3 December 2024.
-
Agriculture to flourish on precision breeding: who will benefit? Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-13
From corn to bananas, farmers stand to gain from cultivating edited crops that are resilient and sustainable, paired with precision insecticides and microbe engineering. But reaching those with the greatest need remains a challenge.
-
A cure for HIV? TCR agents seek to wipe out viral reservoirs Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-07
Bispecific T cell receptor molecules designed to wipe out HIV-infected T cells offer glimpses of a cure.
-
Making space for spatial biology in the clinic Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-06
Spatial transcriptomics methods have been slow to move into clinical practice, but spatial proteomics are cheaper and more scalable, and could progress faster.
-
Publisher Correction: The global patent landscape of functional food innovation Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-03 Maima Matin, Dalibor Hrg, Olena Litvinova, Małgorzata Łysek-Gładysinska, Agnieszka Wierzbicka, Jarosław Olav Horbańczuk, Artur Jóźwik, Atanas G. Atanasov
Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02410-0, published online 14 October 2024.
-
A DNA language model based on multispecies alignment predicts the effects of genome-wide variants Nat. Biotechnol. (IF 33.1) Pub Date : 2025-01-02 Gonzalo Benegas, Carlos Albors, Alan J. Aw, Chengzhong Ye, Yun S. Song
-
NIS-Seq enables cell-type-agnostic optical perturbation screening Nat. Biotechnol. (IF 33.1) Pub Date : 2024-12-19 Caroline I. Fandrey, Marius Jentzsch, Peter Konopka, Alexander Hoch, Katja Blumenstock, Afraa Zackria, Salie Maasewerd, Marta Lovotti, Dorothee J. Lapp, Florian N. Gohr, Piotr Suwara, Jędrzej Świeżewski, Lukas Rossnagel, Fabienne Gobs, Maia Cristodaro, Lina Muhandes, Rayk Behrendt, Martin C. Lam, Klaus J. Walgenbach, Tobias Bald, Florian I. Schmidt, Eicke Latz, Jonathan L. Schmid-Burgk
-
Toward a safer and more secure US bioeconomy Nat. Biotechnol. (IF 33.1) Pub Date : 2024-12-16 Matthew C. Watson, Kunal J. Rambhia, Meghan J. Seltzer, Sarah R. Carter, Rebecca L. Moritz, Aurelia Attal-Juncqua, James Diggans, John Dileo
To enhance the safety and security of the US bioeconomy, a new public–private partnership should be established to facilitate information sharing and threat analysis among industry, government and academia, and to develop and deploy safeguards.